{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:40:39Z","timestamp":1792788039262,"version":"4.5.0"},"reference-count":138,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"This research was supported by the Muscular Dystrophy Association Cyprus\/Telethon Cyprus.","award":["This research was supported by the Muscular Dystrophy Association Cyprus\/Telethon Cyprus."],"award-info":[{"award-number":["This research was supported by the Muscular Dystrophy Association Cyprus\/Telethon Cyprus."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06937-x","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:15:31Z","timestamp":1762521331000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Integrating imaging and omics for enhanced subtyping of mild cognitive impairment associated with Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"23","author":[{"given":"Sotiroula","family":"Afxenti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Zachariou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efi","family":"Athieniti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Lambrianides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marios","family":"Pantzaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George M.","family":"Spyrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"6937_CR1","unstructured":"Long S, Benoist C, Weidner W. World Alzheimer Report 2024. 2024. p. 94."},{"issue":"8","key":"6937_CR2","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","volume":"6","author":"B Dubois","year":"2007","unstructured":"Dubois B, et al. Research criteria for the diagnosis of Alzheimer\u2019s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734\u201346. https:\/\/doi.org\/10.1016\/S1474-4422(07)70178-3.","journal-title":"Lancet Neurol."},{"issue":"6","key":"6937_CR3","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, et al. Advancing research diagnostic criteria for Alzheimer\u2019s disease: The IWG-2 criteria. Lancet Neurol. 2014;13(6):614\u201329. https:\/\/doi.org\/10.1016\/S1474-4422(14)70090-0.","journal-title":"Lancet Neurol."},{"key":"6937_CR4","doi-asserted-by":"publisher","unstructured":"Jellinger KA. Towards a biological definition of Alzheimer disease. Int J Neurol Neurother. 2019;7(1):535\u201362. https:\/\/doi.org\/10.23937\/2378-3001\/1410095.","DOI":"10.23937\/2378-3001\/1410095"},{"issue":"3","key":"6937_CR5","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2011;7(3):280\u201392. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.003.","journal-title":"Alzheimer\u2019s Dement."},{"issue":"4","key":"6937_CR6","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/j.1600-0447.2008.01326.x","volume":"119","author":"AJ Mitchell","year":"2009","unstructured":"Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia - Meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand. 2009;119(4):252\u201365. https:\/\/doi.org\/10.1111\/j.1600-0447.2008.01326.x.","journal-title":"Acta Psychiatr. Scand."},{"issue":"1","key":"6937_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-023-01484-7","volume":"8","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Chen H, Li R, Sterling K, Song W. Amyloid \u03b2-based therapy for Alzheimer\u2019s disease: challenges, successes and future. Signal Transduct Target Ther. 2023;8(1):1\u201326. https:\/\/doi.org\/10.1038\/s41392-023-01484-7.","journal-title":"Signal Transduct. Target. Ther."},{"key":"6937_CR8","unstructured":"Alzheimer\u2019s Association, \u201cAlzheimer\u2019s disease facts and figures\u201d. 2024."},{"key":"6937_CR9","doi-asserted-by":"publisher","unstructured":"Budd Haeberlein S, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2022;9(2):197\u2013210. https:\/\/doi.org\/10.14283\/jpad.2022.30.","DOI":"10.14283\/jpad.2022.30"},{"issue":"4","key":"6937_CR10","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1002\/alz.12213","volume":"17","author":"DS Knopman","year":"2021","unstructured":"Knopman DS, Jones DT, Greicius MD. Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. Alzheimer\u2019s Dement. 2021;17(4):696\u2013701. https:\/\/doi.org\/10.1002\/alz.12213.","journal-title":"Alzheimer\u2019s Dement."},{"issue":"1","key":"6937_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388(1):9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948.","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"6937_CR12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.14283\/jpad.2023.30","volume":"176","author":"J Cummings","year":"2023","unstructured":"Cummings J, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimer\u2019s Dis. 2023;176(5):139\u201348. https:\/\/doi.org\/10.14283\/jpad.2023.30.","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"issue":"6","key":"6937_CR13","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, et al. Donanemab in early symptomatic alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512\u201327. https:\/\/doi.org\/10.1001\/jama.2023.13239.","journal-title":"JAMA"},{"key":"6937_CR14","doi-asserted-by":"publisher","unstructured":"Yiannopoulou KG, Papageorgiou SG. Current and future treatments in Alzheimer disease: an update. J Cent Nerv Syst Dis. 2020;12. https:\/\/doi.org\/10.1177\/1179573520907397.","DOI":"10.1177\/1179573520907397"},{"issue":"4","key":"6937_CR15","doi-asserted-by":"publisher","first-page":"566","DOI":"10.25259\/JNRP_356_2023","volume":"14","author":"A Varadharajan","year":"2023","unstructured":"Varadharajan A, et al. Guidelines for pharmacotherapy in Alzheimer\u2019s disease - A primer on FDA-approved drugs. J Neurosci Rural Pract. 2023;14(4):566\u201373. https:\/\/doi.org\/10.25259\/JNRP_356_2023.","journal-title":"J. Neurosci. Rural Pract."},{"issue":"3","key":"6937_CR16","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1001\/jama.291.3.317","volume":"291","author":"PN Tariot","year":"2004","unstructured":"Tariot PN, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317\u201324. https:\/\/doi.org\/10.1001\/jama.291.3.317.","journal-title":"JAMA"},{"issue":"12","key":"6937_CR17","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1001\/jamaneurol.2023.3810","volume":"80","author":"D Lee","year":"2023","unstructured":"Lee D, et al. Brexpiprazole for the treatment of agitation in Alzheimer dementia: a randomized clinical trial. JAMA Neurol. 2023;80(12):1307\u201316. https:\/\/doi.org\/10.1001\/jamaneurol.2023.3810.","journal-title":"JAMA Neurol."},{"issue":"11","key":"6937_CR18","doi-asserted-by":"publisher","first-page":"8002","DOI":"10.1002\/alz.14282","volume":"20","author":"Y Nakamura","year":"2024","unstructured":"Nakamura Y, et al. Brexpiprazole treatment for agitation in Alzheimer\u2019s dementia: a randomized study. Alzheimers Dement. 2024;20(11):8002\u201311. https:\/\/doi.org\/10.1002\/alz.14282.","journal-title":"Alzheimers. Dement."},{"issue":"7","key":"6937_CR19","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1001\/archneur.62.7.1160","volume":"62","author":"RC Petersen","year":"2005","unstructured":"Petersen RC, Morris JC. Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol. 2005;62(7):1160\u20133. https:\/\/doi.org\/10.1001\/archneur.62.7.1160.","journal-title":"Arch. Neurol."},{"issue":"9","key":"6937_CR20","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1001\/archneurol.2009.106","volume":"66","author":"ST Farias","year":"2009","unstructured":"Farias ST, Mungas D, Reed BR, Harvey D, DeCarli C. Progression of mild cognitive impairment to dementia in clinic- vs community-based cohorts. Arch Neurol. 2009;66(9):1151\u20137. https:\/\/doi.org\/10.1001\/archneurol.2009.106.","journal-title":"Arch. Neurol."},{"issue":"2","key":"6937_CR21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1017\/S1041610204000092","volume":"16","author":"M Bruscoli","year":"2004","unstructured":"Bruscoli M, Lovestone S. Is MCI really just early dementia? A systematic review of conversion studies. Int Psychogeriatrics. 2004;16(2):129\u201340. https:\/\/doi.org\/10.1017\/S1041610204000092.","journal-title":"Int. Psychogeriatrics"},{"issue":"1","key":"6937_CR22","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jalz.2012.09.017","volume":"10","author":"F Jessen","year":"2014","unstructured":"Jessen F, et al. AD dementia risk in late MCI, in early MCI, and in subjective memory impairment. Alzheimer\u2019s Dement. 2014;10(1):76\u201383. https:\/\/doi.org\/10.1016\/j.jalz.2012.09.017.","journal-title":"Alzheimer\u2019s Dement."},{"issue":"3","key":"6937_CR23","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jalz.2010.03.006","volume":"6","author":"PS Aisen","year":"2010","unstructured":"Aisen PS, et al. Clinical core of the Alzheimer\u2019s disease neuroimaging initiative: progress and plans. Alzheimers Dement. 2010;6(3):239\u201346. https:\/\/doi.org\/10.1016\/j.jalz.2010.03.006.","journal-title":"Alzheimers. Dement."},{"key":"6937_CR24","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.neurobiolaging.2018.01.009","volume":"65","author":"K Poulakis","year":"2018","unstructured":"Poulakis K, et al. Heterogeneous patterns of brain atrophy in Alzheimer\u2019s disease. Neurobiol Aging. 2018;65:98\u2013108. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2018.01.009.","journal-title":"Neurobiol. Aging"},{"issue":"2","key":"6937_CR25","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/ana.25142","volume":"83","author":"JL Whitwell","year":"2018","unstructured":"Whitwell JL, et al. [18F]AV-1451 clustering of entorhinal and cortical uptake in Alzheimer\u2019s disease. Ann Neurol. 2018;83(2):248\u201357. https:\/\/doi.org\/10.1002\/ana.25142.","journal-title":"Ann. Neurol."},{"issue":"7","key":"6937_CR26","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.jalz.2019.03.014","volume":"15","author":"MM Machulda","year":"2019","unstructured":"Machulda MM, et al. Neuropsychological subtypes of incident mild cognitive impairment in the Mayo Clinic Study of Aging. Alzheimers Dement. 2019;15(7):878\u201387. https:\/\/doi.org\/10.1016\/j.jalz.2019.03.014.","journal-title":"Alzheimers. Dement."},{"key":"6937_CR27","doi-asserted-by":"publisher","unstructured":"Hwang J, et al. Prediction of Alzheimer\u2019s disease pathophysiology based on cortical thickness patterns. Alzheimer\u2019s Dement Diagnosis Assess Dis Monit. 2016;2:58\u201367. https:\/\/doi.org\/10.1016\/j.dadm.2015.11.008.","DOI":"10.1016\/j.dadm.2015.11.008"},{"issue":"3","key":"6937_CR28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1001\/jamanetworkopen.2020.0413","volume":"3","author":"AE Blanken","year":"2020","unstructured":"Blanken AE, et al. Distilling heterogeneity of mild cognitive impairment in the national Alzheimer coordinating center database using latent profile analysis. JAMA Netw Open. 2020;3(3):10\u20134. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.0413.","journal-title":"JAMA Netw. Open"},{"issue":"8","key":"6937_CR29","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.tins.2011.05.005","volume":"34","author":"M Ewers","year":"2011","unstructured":"Ewers M, Sperling RA, Klunk WE, Weiner MW, Hampel H. Neuroimaging markers for the prediction and early diagnosis of Alzheimer\u2019s disease dementia. Trends Neurosci. 2011;34(8):430\u201342. https:\/\/doi.org\/10.1016\/j.tins.2011.05.005.","journal-title":"Trends Neurosci."},{"issue":"12","key":"6937_CR30","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1093\/brain\/awaa325","volume":"143","author":"BM Tijms","year":"2020","unstructured":"Tijms BM, et al. Pathophysiological subtypes of Alzheimer\u2019s disease based on cerebrospinal fluid proteomics. Brain. 2020;143(12):3776\u201392. https:\/\/doi.org\/10.1093\/brain\/awaa325.","journal-title":"Brain"},{"issue":"1","key":"6937_CR31","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s43587-023-00550-7","volume":"4","author":"BM Tijms","year":"2024","unstructured":"Tijms BM, et al. Cerebrospinal fluid proteomics in patients with Alzheimer\u2019s disease reveals five molecular subtypes with distinct genetic risk profiles. Nat Aging. 2024;4(1):33\u201347. https:\/\/doi.org\/10.1038\/s43587-023-00550-7.","journal-title":"Nat. Aging"},{"key":"6937_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12859-022-04946-x","volume":"23","author":"Y Feng","year":"2022","unstructured":"Feng Y, Kim M, Yao X, Liu K, Long Q, Shen L. Deep multiview learning to identify imaging-driven subtypes in mild cognitive impairment. BMC Bioinformatics. 2022;23:1\u201322. https:\/\/doi.org\/10.1186\/s12859-022-04946-x.","journal-title":"BMC Bioinformatics"},{"issue":"2","key":"6937_CR33","doi-asserted-by":"publisher","first-page":"224","DOI":"10.14283\/jpad.2020.65","volume":"8","author":"HT Li","year":"2021","unstructured":"Li HT, Yuan SX, Wu JS, Zhang XZ, Liu Y, Sun X. Molecular subtyping of mild cognitive impairment based on genetic polymorphism and gene expression. J Prev Alzheimer\u2019s Dis. 2021;8(2):224\u201333. https:\/\/doi.org\/10.14283\/jpad.2020.65.","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"issue":"46","key":"6937_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/sciadv.abo6764","volume":"8","author":"Y Iturria-Medina","year":"2022","unstructured":"Iturria-Medina Y, et al. Unified epigenomic, transcriptomic, proteomic, and metabolomic taxonomy of Alzheimer\u2019s disease progression and heterogeneity. Sci Adv. 2022;8(46):1\u201318. https:\/\/doi.org\/10.1126\/sciadv.abo6764.","journal-title":"Sci. Adv."},{"issue":"6","key":"6937_CR35","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1038\/s41380-022-01886-z","volume":"28","author":"B Avelar-Pereira","year":"2023","unstructured":"Avelar-Pereira B, Belloy ME, O\u2019Hara R, Hosseini SMH. Decoding the heterogeneity of Alzheimer\u2019s disease diagnosis and progression using multilayer networks. Mol Psychiatry. 2023;28(6):2423\u201332. https:\/\/doi.org\/10.1038\/s41380-022-01886-z.","journal-title":"Mol. Psychiatry"},{"issue":"4","key":"6937_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/braincomms\/fcae219","volume":"6","author":"M Estarellas","year":"2024","unstructured":"Estarellas M, Oxtoby NP, Schott JM, Alexander DC, Young AL. Multimodal subtypes identified in Alzheimer\u2019s disease neuroimaging initiative participants by missing-data-enabled subtype and stage inference. Brain Commun. 2024;6(4):1\u201315. https:\/\/doi.org\/10.1093\/braincomms\/fcae219.","journal-title":"Brain Commun."},{"key":"6937_CR37","doi-asserted-by":"publisher","unstructured":"Eteleeb AM, et al. Brain high-throughput multi-omics data reveal molecular heterogeneity in Alzheimer\u2019s disease, vol. 22, no. 4. 2024. https:\/\/doi.org\/10.1371\/journal.pbio.3002607.","DOI":"10.1371\/journal.pbio.3002607"},{"key":"6937_CR38","doi-asserted-by":"publisher","unstructured":"Li HT, Yuan SX, Wu JS, Gu Y, Sun X. Predicting conversion from mci to ad combining multi-modality data and based on molecular subtype. Brain Sci. 2021;11(6). https:\/\/doi.org\/10.3390\/brainsci11060674.","DOI":"10.3390\/brainsci11060674"},{"key":"6937_CR39","doi-asserted-by":"publisher","first-page":"5296","DOI":"10.1016\/j.csbj.2022.08.007","volume":"20","author":"M Kikuchi","year":"2022","unstructured":"Kikuchi M, et al. Identification of mild cognitive impairment subtypes predicting conversion to Alzheimer\u2019s disease using multimodal data. Comput Struct Biotechnol J. 2022;20:5296\u2013308. https:\/\/doi.org\/10.1016\/j.csbj.2022.08.007.","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"3","key":"6937_CR40","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nmeth.2810","volume":"11","author":"B Wang","year":"2014","unstructured":"Wang B, et al. Similarity network fusion for aggregating data types on a genomic scale. Nat Methods. 2014;11(3):333\u20137. https:\/\/doi.org\/10.1038\/nmeth.2810.","journal-title":"Nat. Methods"},{"key":"6937_CR41","doi-asserted-by":"publisher","unstructured":"Markello RD, Shafiei G, Tremblay C, Postuma RB, Dagher A, Misic B. Multimodal phenotypic axes of Parkinson\u2019s disease. npj Park Dis. 2021;7(1). https:\/\/doi.org\/10.1038\/s41531-020-00144-9.","DOI":"10.1038\/s41531-020-00144-9"},{"key":"6937_CR42","doi-asserted-by":"publisher","unstructured":"Mueller SG, et al. The Alzheimer\u2019s disease neuroimaging initiative. Neuroimaging Clin N Am. 2005;15(4):869\u201377. https:\/\/doi.org\/10.1016\/j.nic.2005.09.008.","DOI":"10.1016\/j.nic.2005.09.008"},{"issue":"17","key":"6937_CR43","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1093\/bioinformatics\/bty1054","volume":"35","author":"A Singh","year":"2019","unstructured":"Singh A, et al. DIABLO: An integrative approach for identifying key molecular drivers from multi-omics assays. Bioinformatics. 2019;35(17):3055\u201362. https:\/\/doi.org\/10.1093\/bioinformatics\/bty1054.","journal-title":"Bioinformatics"},{"key":"6937_CR44","doi-asserted-by":"publisher","unstructured":"Shaw L, et al. Report and future plans, vol. 6, no. 3. 2010. https:\/\/doi.org\/10.1016\/j.jalz.2010.03.007.The.","DOI":"10.1016\/j.jalz.2010.03.007.The"},{"key":"6937_CR45","unstructured":"the ADNI team. ADNIMERGE: Alzheimer\u2019s disease neuroimaging initiative. 2023."},{"issue":"4","key":"6937_CR46","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/jmri.21049","volume":"27","author":"CR Jack","year":"2008","unstructured":"Jack CR, et al. The Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008;27(4):685\u201391. https:\/\/doi.org\/10.1002\/jmri.21049.","journal-title":"J. Magn. Reson. Imaging"},{"key":"6937_CR47","doi-asserted-by":"publisher","unstructured":"Voevodskaya O. The effects of intracranial volume adjustment approaches on multiple regional MRI volumes in healthy aging and Alzheimer\u2019s disease. Front Aging Neurosci. 2014;6(OCT):1\u201314. https:\/\/doi.org\/10.3389\/fnagi.2014.00264.","DOI":"10.3389\/fnagi.2014.00264"},{"issue":"7\u20138","key":"6937_CR48","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/prca.201400178","volume":"9","author":"DS Spellman","year":"2015","unstructured":"Spellman DS, et al. Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI) CSF. Proteomics - Clin Appl. 2015;9(7\u20138):715\u201331. https:\/\/doi.org\/10.1002\/prca.201400178.","journal-title":"Proteomics - Clin. Appl."},{"key":"6937_CR49","unstructured":"Wang B, et al. SNFtool: similarity network fusion. 2021. [Online]. Available: https:\/\/cran.r-project.org\/package=SNFtool."},{"key":"6937_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/C2009-0-27609-4","author":"Probabilistic Reasoning in Intelligent Systems","year":"1988","unstructured":"Probabilistic Reasoning in Intelligent Systems. Elsevier. 1988. https:\/\/doi.org\/10.1016\/C2009-0-27609-4.","journal-title":"Elsevier"},{"issue":"12","key":"6937_CR51","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1093\/bioinformatics\/bty050","volume":"34","author":"S Park","year":"2018","unstructured":"Park S, Zhao H. Spectral clustering based on learning similarity matrix. Bioinformatics. 2018;34(12):2069\u201376. https:\/\/doi.org\/10.1093\/bioinformatics\/bty050.","journal-title":"Bioinformatics"},{"key":"6937_CR52","doi-asserted-by":"publisher","unstructured":"Huang J, Nie F, Huang H. Spectral rotation versus K-Means in spectral clustering. In: Proceedings of the 27th International Joint Conference on Artificial Intelligence. AAAI 2013, no. 2, pp. 431\u20137. 2013. https:\/\/doi.org\/10.1609\/aaai.v27i1.8683.","DOI":"10.1609\/aaai.v27i1.8683"},{"issue":"7","key":"6937_CR53","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7). https:\/\/doi.org\/10.1093\/nar\/gkv007.","journal-title":"Nucleic Acids Res."},{"issue":"10","key":"6937_CR54","doi-asserted-by":"publisher","first-page":"7350","DOI":"10.1002\/alz.14166","volume":"20","author":"CR Jack","year":"2024","unstructured":"Jack CR, et al. Overview of ADNI MRI. Alzheimer\u2019s Dement. 2024;20(10):7350\u201360. https:\/\/doi.org\/10.1002\/alz.14166.","journal-title":"Alzheimer\u2019s Dement."},{"key":"6937_CR55","doi-asserted-by":"publisher","unstructured":"Wu T, et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation. 2021;2(3):100141. https:\/\/doi.org\/10.1016\/j.xinn.2021.100141.","DOI":"10.1016\/j.xinn.2021.100141"},{"issue":"1","key":"6937_CR56","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov MV, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44(1):W90\u20137. https:\/\/doi.org\/10.1093\/nar\/gkw377.","journal-title":"Nucleic Acids Res."},{"key":"6937_CR57","doi-asserted-by":"publisher","unstructured":"Rohart F, Gautier B, Singh A, L\u00ea Cao KA. mixOmics: an R package for \u2018omics\u2019 feature selection and multiple data integration. PLoS Comput Biol. 2017;13(11):1\u201319. https:\/\/doi.org\/10.1371\/journal.pcbi.1005752.","DOI":"10.1371\/journal.pcbi.1005752"},{"issue":"22","key":"6937_CR58","doi-asserted-by":"publisher","first-page":"12182","DOI":"10.1073\/pnas.220392197","volume":"97","author":"AJ Butte","year":"2000","unstructured":"Butte AJ, Tamayo P, Slonim D, Golub TR, Kohane IS. Discovering functional relationships between RNA expression and chemotherapeutic susceptibility using relevance networks. Proc Natl Acad Sci USA. 2000;97(22):12182\u20136. https:\/\/doi.org\/10.1073\/pnas.220392197.","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"6937_CR59","first-page":"199","volume":"2","author":"M Moriyama","year":"2003","unstructured":"Moriyama M, et al. Relevance network between chemosensitivity and transcriptome in human hepatoma cells. Mol Cancer Ther. 2003;2(2):199\u2013205.","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"6937_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1756-0381-5-19","volume":"5","author":"I Gonz\u00e1lez","year":"2012","unstructured":"Gonz\u00e1lez I, Cao KAL, Davis MJ, D\u00e9jean S. Visualising associations between paired \u2018omics\u2019 data sets. BioData Min. 2012;5(1):1\u201323. https:\/\/doi.org\/10.1186\/1756-0381-5-19.","journal-title":"BioData Min."},{"key":"6937_CR61","doi-asserted-by":"publisher","unstructured":"N. Turck et al., \u201cpROC: an open-source package for R and S+ to analyze and compare ROC curves,\u201d BMC Bioinformatics, vol. 8, pp. 12\u201377, 2011, [Online]. Available: http:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/s00134-009-1641-y","DOI":"10.1007\/s00134-009-1641-y"},{"issue":"6","key":"6937_CR62","doi-asserted-by":"publisher","first-page":"665","DOI":"10.5351\/csam.2015.22.6.665","volume":"22","author":"S Kim","year":"2015","unstructured":"Kim S. ppcor: An R Package for a Fast Calculation to Semi-partial Correlation Coefficients. Commun Stat Appl Methods. 2015;22(6):665\u201374. https:\/\/doi.org\/10.5351\/csam.2015.22.6.665.","journal-title":"Commun. Stat. Appl. Methods"},{"key":"6937_CR63","doi-asserted-by":"publisher","unstructured":"Gu Z. Complex heatmap visualization. iMeta. 2022;1(3):1\u201315. https:\/\/doi.org\/10.1002\/imt2.43.","DOI":"10.1002\/imt2.43"},{"issue":"1","key":"6937_CR64","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/nar\/30.1.207","volume":"30","author":"R Edgar","year":"2002","unstructured":"Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207\u201310. https:\/\/doi.org\/10.1093\/nar\/30.1.207.","journal-title":"Nucleic Acids Res."},{"issue":"D1","key":"6937_CR65","doi-asserted-by":"publisher","first-page":"D138","DOI":"10.1093\/nar\/gkad965","volume":"52","author":"E Clough","year":"2024","unstructured":"Clough E, et al. NCBI GEO: archive for gene expression and epigenomics data sets: 23-year update. Nucleic Acids Res. 2024;52(D1):D138\u201344. https:\/\/doi.org\/10.1093\/nar\/gkad965.","journal-title":"Nucleic Acids Res."},{"key":"6937_CR66","doi-asserted-by":"publisher","unstructured":"Wang Z, He E, Sani K, Jagodnik KM, Silverstein MC, Ma\u2019Ayan A. Drug Gene Budger (DGB): an application for ranking drugs to modulate a specific gene based on transcriptomic signatures. Bioinformatics. 2019;35(7):1247\u20138. https:\/\/doi.org\/10.1093\/bioinformatics\/bty763.","DOI":"10.1093\/bioinformatics\/bty763"},{"issue":"6","key":"6937_CR67","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","volume":"171","author":"A Subramanian","year":"2017","unstructured":"Subramanian A, et al. A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell. 2017;171(6):1437.e17\u201352.e17. https:\/\/doi.org\/10.1016\/j.cell.2017.10.049.","journal-title":"Cell"},{"key":"6937_CR68","doi-asserted-by":"publisher","unstructured":"Lamb J, et al. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313(5795):1929\u201335. https:\/\/doi.org\/10.1126\/science.1132939.","DOI":"10.1126\/science.1132939"},{"key":"6937_CR69","doi-asserted-by":"publisher","unstructured":"Bourdakou MM, Fern\u00e1ndez-Gin\u00e9s R, Cuadrado A, Spyrou GM. Drug repurposing on Alzheimer\u2019s disease through modulation of NRF2 neighborhood. Redox Biol. 2023;67(August). https:\/\/doi.org\/10.1016\/j.redox.2023.102881.","DOI":"10.1016\/j.redox.2023.102881"},{"issue":"4","key":"6937_CR70","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nm.4306.The","volume":"23","author":"SM Corsello","year":"2017","unstructured":"Corsello SM, et al. The Drug Repurposing Hub. Nat Med. 2017;23(4):405\u20138. https:\/\/doi.org\/10.1038\/nm.4306.The.","journal-title":"Nat. Med."},{"key":"6937_CR71","unstructured":"Jack CR, Hampel HJ, Universities S, Cu M, Petersen RC. A new classification system for AD, independent of cognition A \/ T \/ N\u202f: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;0(July):1\u201310."},{"key":"6937_CR72","doi-asserted-by":"publisher","unstructured":"Quinn JP, Kandigian SE, Trombetta BA, Arnold SE, Carlyle BC. VGF as a biomarker and therapeutic target in neurodegenerative and psychiatric diseases. Brain Commun. 2021;3(4). https:\/\/doi.org\/10.1093\/braincomms\/fcab261.","DOI":"10.1093\/braincomms\/fcab261"},{"key":"6937_CR73","doi-asserted-by":"publisher","unstructured":"Allen M, et al. Human whole genome genotype and transcriptome data for Alzheimer\u2019s and other neurodegenerative diseases. Sci Data. 2016;3(1):160089. https:\/\/doi.org\/10.1038\/sdata.2016.89.","DOI":"10.1038\/sdata.2016.89"},{"key":"6937_CR74","doi-asserted-by":"publisher","unstructured":"Bai B, et al. \u201cHHS Public Access,\u201d vol. 105, no. 6. 2021. pp. 975\u201391. https:\/\/doi.org\/10.1016\/j.neuron.2019.12.015.Deep.","DOI":"10.1016\/j.neuron.2019.12.015.Deep"},{"key":"6937_CR75","doi-asserted-by":"publisher","unstructured":"Neff RA, et al. Molecular subtyping of Alzheimer\u2019s disease using RNA sequencing data reveals novel mechanisms and targets. Sci Adv. 2021;7(2). https:\/\/doi.org\/10.1126\/sciadv.abb5398.","DOI":"10.1126\/sciadv.abb5398"},{"key":"6937_CR76","doi-asserted-by":"publisher","unstructured":"Lian P, et al. Identification and experimental validation of m7G-related molecular subtypes, immune signature, and feature genes in Alzheimer\u2019s disease. Heliyon. 2024;10(13). https:\/\/doi.org\/10.1016\/j.heliyon.2024.e33836.","DOI":"10.1016\/j.heliyon.2024.e33836"},{"issue":"1","key":"6937_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-21256-6","volume":"8","author":"H Liu","year":"2018","unstructured":"Liu H, Luo K, Luo D. Guanosine monophosphate reductase 1 is a potential therapeutic target for Alzheimer\u2019s disease. Sci Rep. 2018;8(1):1\u201310. https:\/\/doi.org\/10.1038\/s41598-018-21256-6.","journal-title":"Sci. Rep."},{"key":"6937_CR78","doi-asserted-by":"publisher","unstructured":"Toshkhujaev S, et al. Classification of Alzheimer\u2019s disease and mild cognitive impairment based on cortical and subcortical features from MRI T1 brain images utilizing four different types of datasets. J Healthc Eng. 2020;2020(Mci). https:\/\/doi.org\/10.1155\/2020\/3743171.","DOI":"10.1155\/2020\/3743171"},{"issue":"1","key":"6937_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-06624-y","volume":"7","author":"D Gamberger","year":"2017","unstructured":"Gamberger D, Lavra\u010d N, Srivatsa S, Tanzi RE, Doraiswamy PM. Identification of clusters of rapid and slow decliners among subjects at risk for Alzheimer\u2019s disease. Sci Rep. 2017;7(1):1\u201312. https:\/\/doi.org\/10.1038\/s41598-017-06624-y.","journal-title":"Sci. Rep."},{"key":"6937_CR80","doi-asserted-by":"publisher","unstructured":"Petersen KK, Nallapu BT, Lipton RB, Grober E, Ezzati A. MRI-guided clustering of patients with mild dementia due to Alzheimer\u2019s disease using self-organizing maps. NeuroImage: Rep. 2024;4(4). https:\/\/doi.org\/10.1016\/j.ynirp.2024.100227.","DOI":"10.1016\/j.ynirp.2024.100227"},{"issue":"1","key":"6937_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12014-020-09276-9","volume":"17","author":"CM Pedrero-Prieto","year":"2020","unstructured":"Pedrero-Prieto CM, et al. A comprehensive systematic review of CSF proteins and peptides that define Alzheimer\u2019s disease. Clin Proteomics. 2020;17(1):1\u201324. https:\/\/doi.org\/10.1186\/s12014-020-09276-9.","journal-title":"Clin. Proteomics"},{"issue":"3","key":"6937_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/proteomes9030036","volume":"9","author":"BM Tijms","year":"2021","unstructured":"Tijms BM, et al. Csf proteomic alzheimer\u2019s disease-predictive subtypes in cognitively intact amyloid negative individuals. Proteomes. 2021;9(3):1\u201315. https:\/\/doi.org\/10.3390\/proteomes9030036.","journal-title":"Proteomes"},{"issue":"3","key":"6937_CR83","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.mehy.2014.06.008","volume":"83","author":"LM Oberman","year":"2014","unstructured":"Oberman LM, Pascual-Leone A. Hyperplasticity in Autism Spectrum Disorder confers protection from Alzheimer\u2019s disease. Med Hypotheses. 2014;83(3):337\u201342. https:\/\/doi.org\/10.1016\/j.mehy.2014.06.008.","journal-title":"Med. Hypotheses"},{"issue":"19","key":"6937_CR84","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1212\/WNL.0b013e3181dd4dd8","volume":"74","author":"\u00c5K Wallin","year":"2010","unstructured":"Wallin \u00c5K, Blennow K, Zetterberg H, Londos E, Minthon L, Hansson O. CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology. 2010;74(19):1531\u20137. https:\/\/doi.org\/10.1212\/WNL.0b013e3181dd4dd8.","journal-title":"Neurology"},{"issue":"12","key":"6937_CR85","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1212\/01.wnl.0000345014.48839.71","volume":"72","author":"AE Van Der Vlies","year":"2009","unstructured":"Van Der Vlies AE, et al. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease. Neurology. 2009;72(12):1056\u201361. https:\/\/doi.org\/10.1212\/01.wnl.0000345014.48839.71.","journal-title":"Neurology"},{"issue":"5","key":"6937_CR86","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/ana.20639","volume":"58","author":"K Iqbal","year":"2005","unstructured":"Iqbal K, et al. Subgroups of Alzheimer\u2019s disease based on cerebrospinal fluid molecular markers. Ann Neurol. 2005;58(5):748\u201357. https:\/\/doi.org\/10.1002\/ana.20639.","journal-title":"Ann. Neurol."},{"issue":"4","key":"6937_CR87","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2217\/bmm.12.42.Upcoming","volume":"6","author":"N Muralitharan","year":"2013","unstructured":"Muralitharan N. Nursing management of the patient with Alzheimer\u2019s disease. Br J Nurs. 2013;6(4):455\u201376. https:\/\/doi.org\/10.2217\/bmm.12.42.Upcoming.","journal-title":"Br. J. Nurs."},{"key":"6937_CR88","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1750-1326-9-53","volume":"9","author":"A Brinkmalm","year":"2014","unstructured":"Brinkmalm A, et al. SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer\u2019s disease. Mol Neurodegener. 2014;9:53. https:\/\/doi.org\/10.1186\/1750-1326-9-53.","journal-title":"Mol. Neurodegener."},{"issue":"4","key":"6937_CR89","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/embor.2013.15","volume":"14","author":"AM Pooler","year":"2013","unstructured":"Pooler AM, Phillips EC, Lau DHW, Noble W, Hanger DP. Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep. 2013;14(4):389\u201394. https:\/\/doi.org\/10.1038\/embor.2013.15.","journal-title":"EMBO Rep."},{"issue":"3","key":"6937_CR90","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1084\/jem.20131685","volume":"211","author":"K Yamada","year":"2014","unstructured":"Yamada K, et al. Neuronal activity regulates extracellular tau in vivo. J Exp Med. 2014;211(3):387\u201393. https:\/\/doi.org\/10.1084\/jem.20131685.","journal-title":"J. Exp. Med."},{"issue":"7","key":"6937_CR91","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.jalz.2018.01.012","volume":"14","author":"CL Sutphen","year":"2018","unstructured":"Sutphen CL, et al. Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2018;14(7):869\u201379. https:\/\/doi.org\/10.1016\/j.jalz.2018.01.012.","journal-title":"Alzheimer\u2019s Dement."},{"issue":"2","key":"6937_CR92","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1523\/JNEUROSCI.4152-10.2011","volume":"31","author":"ED Roberson","year":"2011","unstructured":"Roberson ED, et al. Amyloid-\u03b2\/fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of alzheimer\u2019s disease. J Neurosci. 2011;31(2):700\u201311. https:\/\/doi.org\/10.1523\/JNEUROSCI.4152-10.2011.","journal-title":"J. Neurosci."},{"issue":"12","key":"6937_CR93","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/nrn.2016.141","volume":"17","author":"JJ Palop","year":"2016","unstructured":"Palop JJ, Mucke L. Network abnormalities and interneuron dysfunction in Alzheimer disease. Nat Rev Neurosci. 2016;17(12):777\u201392. https:\/\/doi.org\/10.1038\/nrn.2016.141.","journal-title":"Nat. Rev. Neurosci."},{"issue":"1","key":"6937_CR94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40035-018-0127-7","volume":"7","author":"H Zhang","year":"2018","unstructured":"Zhang H, et al. Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer\u2019s disease. Transl Neurodegener. 2018;7(1):1\u201312. https:\/\/doi.org\/10.1186\/s40035-018-0127-7.","journal-title":"Transl. Neurodegener."},{"issue":"1","key":"6937_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-015-0142-1","volume":"7","author":"MI Kester","year":"2015","unstructured":"Kester MI, et al. Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer\u2019s disease in a memory clinic cohort. Alzheimer\u2019s Res Ther. 2015;7(1):1\u20139. https:\/\/doi.org\/10.1186\/s13195-015-0142-1.","journal-title":"Alzheimer\u2019s Res. Ther."},{"issue":"4","key":"6937_CR96","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3233\/JAD-2011-101911","volume":"25","author":"TT Sepp\u00e4l\u00e4","year":"2011","unstructured":"Sepp\u00e4l\u00e4 TT, Koivisto AM, Hartikainen P, Helisalmi S, Soininen H, Herukka SK. Longitudinal changes of CSF biomarkers in alzheimer\u2019s disease. J Alzheimer\u2019s Dis. 2011;25(4):583\u201394. https:\/\/doi.org\/10.3233\/JAD-2011-101911.","journal-title":"J. Alzheimer\u2019s Dis."},{"issue":"June","key":"6937_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphys.2020.00598","volume":"11","author":"H Chew","year":"2020","unstructured":"Chew H, Solomon VA, Fonteh AN. Involvement of lipids in Alzheimer\u2019s disease pathology and potential therapies. Front Physiol. 2020;11(June):1\u201328. https:\/\/doi.org\/10.3389\/fphys.2020.00598.","journal-title":"Front. Physiol."},{"issue":"3","key":"6937_CR98","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrneurol.2017.188.Blood","volume":"14","author":"MD Sweeney","year":"2018","unstructured":"Sweeney MD, Sagare AP, Zlokovic BV. Blood\u2013brain barrier breakdown in Alzheimer\u2019s disease and other.pdf. Nat Rev Neurol. 2018;14(3):133\u201350. https:\/\/doi.org\/10.1038\/nrneurol.2017.188.Blood.","journal-title":"Nat. Rev. Neurol."},{"key":"6937_CR99","doi-asserted-by":"publisher","unstructured":"Yamazaki Y, Kanekiyo T. Blood-brain barrier dysfunction and the pathogenesis of Alzheimer\u2019s disease. Int J Mol Sci. 2017;18(9). https:\/\/doi.org\/10.3390\/ijms18091965.","DOI":"10.3390\/ijms18091965"},{"issue":"1","key":"6937_CR100","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/braincomms\/fcae050","volume":"6","author":"D Negro","year":"2024","unstructured":"Negro D, Opazo P. Cognitive resilience in Alzheimer\u2019s disease: from large-scale brain networks to synapses. Brain Commun. 2024;6(1):14\u20137. https:\/\/doi.org\/10.1093\/braincomms\/fcae050.","journal-title":"Brain Commun."},{"issue":"41","key":"6937_CR101","doi-asserted-by":"publisher","first-page":"6833","DOI":"10.1523\/JNEUROSCI.0379-23.2023","volume":"43","author":"N Bhembre","year":"2023","unstructured":"Bhembre N, Bonthron C, Opazo P. Synaptic compensatory plasticity in Alzheimer\u2019s disease. J Neurosci. 2023;43(41):6833\u201340. https:\/\/doi.org\/10.1523\/JNEUROSCI.0379-23.2023.","journal-title":"J. Neurosci."},{"key":"6937_CR102","doi-asserted-by":"publisher","unstructured":"Lin C-Y, Chen C-H, Tom SE, Kuo S-H, Alzheimer\u2019s Disease Neuroimaging Initiative. Cerebellar volume is associated with cognitive decline in mild cognitive impairment: results from ADNI. Cerebellum. 2020;19(2):217\u201325. https:\/\/doi.org\/10.1007\/s12311-019-01099-1.","DOI":"10.1007\/s12311-019-01099-1"},{"issue":"4","key":"6937_CR103","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/nn.3045.Plasticity","volume":"15","author":"RJ Zatorre","year":"2012","unstructured":"Zatorre RJ, Fields RD, Johansen-Berg H. Plasticity in gray and white. Nat Neurosci. 2012;15(4):528\u201336. https:\/\/doi.org\/10.1038\/nn.3045.Plasticity.","journal-title":"Nat. Neurosci."},{"issue":"1","key":"6937_CR104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-023-40208-x","volume":"14","author":"M Askenazi","year":"2023","unstructured":"Askenazi M, Kavanagh T, Pires G, Ueberheide B, Wisniewski T, Drummond E. Compilation of reported protein changes in the brain in Alzheimer\u2019s disease. Nat Commun. 2023;14(1):1\u201315. https:\/\/doi.org\/10.1038\/s41467-023-40208-x.","journal-title":"Nat. Commun."},{"key":"6937_CR105","doi-asserted-by":"publisher","unstructured":"Whitwell JL, et al. NIH Public Access, vol. 70, no. 7. 2009. pp. 512\u201320. https:\/\/doi.org\/10.1212\/01.wnl.0000280575.77437.a2.MRI.","DOI":"10.1212\/01.wnl.0000280575.77437.a2.MRI"},{"key":"6937_CR106","doi-asserted-by":"publisher","unstructured":"Begcevic I, et al. Neuronal pentraxin receptor-1 is a new cerebrospinal fluid biomarker of Alzheimer\u2019s disease progression. F1000Research. 2018;7(0). https:\/\/doi.org\/10.12688\/F1000RESEARCH.15095.1.","DOI":"10.12688\/F1000RESEARCH.15095.1"},{"key":"6937_CR107","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1155\/2014\/796869","volume":"2014","author":"JR Ou","year":"2014","unstructured":"Ou JR, Tan MS, Xie AM, Yu JT, Tan L. Heat shock protein 90 in Alzheimer\u2019s disease. Biomed Res Int. 2014;2014:6\u20138. https:\/\/doi.org\/10.1155\/2014\/796869.","journal-title":"Biomed Res. Int."},{"key":"6937_CR108","doi-asserted-by":"publisher","unstructured":"Jhaveri K, Modi S. HSP90 inhibitors for cancer therapy and overcoming drug resistance, vol. 65. Elsevier Inc. 2012. https:\/\/doi.org\/10.1016\/B978-0-12-397927-8.00015-4.","DOI":"10.1016\/B978-0-12-397927-8.00015-4"},{"issue":"4","key":"6937_CR109","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.3233\/JAD-140066","volume":"41","author":"L Zhang","year":"2014","unstructured":"Zhang L, et al. Tubastatin A\/ACY-1215 improves cognition in Alzheimer\u2019s disease transgenic mice. J Alzheimer\u2019s Dis. 2014;41(4):1193\u2013205. https:\/\/doi.org\/10.3233\/JAD-140066.","journal-title":"J. Alzheimer\u2019s Dis."},{"issue":"11","key":"6937_CR110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/foods13111774","volume":"13","author":"G Genchi","year":"2024","unstructured":"Genchi G, Lauria G, Catalano A, Carocci A, Sinicropi MS. Neuroprotective effects of curcumin in neurodegenerative diseases. Foods. 2024;13(11):1\u201314. https:\/\/doi.org\/10.3390\/foods13111774.","journal-title":"Foods"},{"key":"6937_CR111","doi-asserted-by":"publisher","unstructured":"M\u00fchlbauer V, M\u00f6hler R, Mn D, Su Z, K\u00f6pke S, Hj L. Antipsychotics for agitation and psychosis in people with Alzheimer\u2019s disease and vascular dementia (Review). 2021. https:\/\/doi.org\/10.1002\/14651858.CD013304.pub2.www.cochranelibrary.com.","DOI":"10.1002\/14651858.CD013304.pub2.www.cochranelibrary.com"},{"issue":"7","key":"6937_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.104052","volume":"29","author":"M Pereira","year":"2024","unstructured":"Pereira M, Cruz MT, Fortuna A, Bicker J. Restoring the epigenome in Alzheimer\u2019s disease: advancing HDAC inhibitors as therapeutic agents. Drug Discov Today. 2024;29(7). https:\/\/doi.org\/10.1016\/j.drudis.2024.104052.","journal-title":"Drug Discov. Today"},{"issue":"1","key":"6937_CR113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-024-01384-0","volume":"16","author":"M Zhang","year":"2024","unstructured":"Zhang M, et al. Histone deacetylase inhibitors VPA and WT161 ameliorate the pathological features and cognitive impairments of the APP\/PS1 Alzheimer\u2019s disease mouse model by regulating the expression of APP secretases. Alzheimer\u2019s Res Ther. 2024;16(1):1\u201320. https:\/\/doi.org\/10.1186\/s13195-024-01384-0.","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"6937_CR114","unstructured":"Chacko S, Ladiges W. Alzheimer\u2019s disease. 2022."},{"issue":"1","key":"6937_CR115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-020-00746-8","volume":"13","author":"Q Su","year":"2021","unstructured":"Su Q, et al. Trichostatin A ameliorates Alzheimer\u2019s disease-related pathology and cognitive deficits by increasing albumin expression and A\u03b2 clearance in APP\/PS1 mice. Alzheimer\u2019s Res Ther. 2021;13(1):1\u201315. https:\/\/doi.org\/10.1186\/s13195-020-00746-8.","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"6937_CR116","doi-asserted-by":"publisher","unstructured":"Mao R, et al. Triptolide injection reduces Alzheimer\u2019s disease-like pathology in mice. Synapse. 2023;77(3):e22261. https:\/\/doi.org\/10.1002\/syn.22261.","DOI":"10.1002\/syn.22261"},{"issue":"3","key":"6937_CR117","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/etm.2023.12139","volume":"26","author":"L Zhou","year":"2023","unstructured":"Zhou L, Huang X, Li H, Wang J, Lu Z. Triptolide improves Alzheimer\u2019s disease by regulating the NF-\u03baB signaling pathway through the lncRNA NEAT1\/microRNA 361\u20133p\/TRAF2 axis. Exp Ther Med. 2023;26(3):1\u201311. https:\/\/doi.org\/10.3892\/etm.2023.12139.","journal-title":"Exp. Ther. Med."},{"key":"6937_CR118","doi-asserted-by":"publisher","unstructured":"Kang Y, Tiziani S, Park G, Kaul M, Paternostro G. Cellular protection using Flt3 and PI3Ka inhibitors demonstrates multiple mechanisms of oxidative glutamate toxicity. Nat Commun. 2014;5. https:\/\/doi.org\/10.1038\/ncomms4672.","DOI":"10.1038\/ncomms4672"},{"key":"6937_CR119","doi-asserted-by":"publisher","unstructured":"Afghah Z, Khan N, Datta G, Halcrow PW, Geiger JD, Chen X. Involvement of endolysosomes and aurora kinase A in the regulation of amyloid \u03b2 protein levels in neurons. Int J Mol Sci. 2024;25(11). https:\/\/doi.org\/10.3390\/ijms25116200.","DOI":"10.3390\/ijms25116200"},{"key":"6937_CR120","doi-asserted-by":"publisher","unstructured":"Saleh B, et al. FAK-mediated signaling controls amyloid beta overload, learning and memory deficits in a mouse model of Alzheimer\u2019s disease. Int J Mol Sci. 2022;23(16). https:\/\/doi.org\/10.3390\/ijms23169055.","DOI":"10.3390\/ijms23169055"},{"issue":"7","key":"6937_CR121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.26508\/lsa.202302423","volume":"7","author":"T Toshima","year":"2024","unstructured":"Toshima T, et al. Mitochondrial translation failure represses cholesterol gene expression via Pyk2-Gsk3\u03b2-Srebp2 axis. Life Sci Alliance. 2024;7(7):1\u201315. https:\/\/doi.org\/10.26508\/lsa.202302423.","journal-title":"Life Sci. Alliance"},{"key":"6937_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2021.105115","volume":"148","author":"N Malhotra","year":"2021","unstructured":"Malhotra N, Gupta R, Kumar P. Pharmacological relevance of CDK inhibitors in Alzheimer\u2019s disease. Neurochem Int. 2021;148. https:\/\/doi.org\/10.1016\/j.neuint.2021.105115.","journal-title":"Neurochem. Int."},{"key":"6937_CR123","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.pharmthera.2015.10.002","volume":"156","author":"P Wu","year":"2015","unstructured":"Wu P, Clausen MH, Nielsen TE. Allosteric small-molecule kinase inhibitors. Pharmacol Ther. 2015;156:59\u201368. https:\/\/doi.org\/10.1016\/j.pharmthera.2015.10.002.","journal-title":"Pharmacol. Ther."},{"issue":"2","key":"6937_CR124","doi-asserted-by":"publisher","first-page":"e22778","DOI":"10.1096\/fj.202201512R","volume":"37","author":"L Schn\u00f6der","year":"2023","unstructured":"Schn\u00f6der L, et al. Deficiency of IKK\u03b2 in neurons ameliorates Alzheimer\u2019s disease pathology in APP- and tau-transgenic mice. FASEB J. 2023;37(2):e22778.","journal-title":"FASEB J"},{"key":"6937_CR125","doi-asserted-by":"publisher","unstructured":"Yamaguchi T, et al. Syk inhibitors reduce tau protein phosphorylation and oligomerization. Neurobiol Dis. 2024;201(September):106656. https:\/\/doi.org\/10.1016\/j.nbd.2024.106656.","DOI":"10.1016\/j.nbd.2024.106656"},{"issue":"10","key":"6937_CR126","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41582-019-0244-7","volume":"15","author":"Y Hou","year":"2019","unstructured":"Hou Y, et al. Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol. 2019;15(10):565\u201381. https:\/\/doi.org\/10.1038\/s41582-019-0244-7.","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"6937_CR127","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40035-024-00397-x","volume":"13","author":"Y Liu","year":"2024","unstructured":"Liu Y, Tan Y, Zhang Z, Yi M, Zhu L, Peng W. The interaction between ageing and Alzheimer\u2019s disease: insights from the hallmarks of ageing. Transl Neurodegener. 2024;13(1):7. https:\/\/doi.org\/10.1186\/s40035-024-00397-x.","journal-title":"Transl. Neurodegener."},{"key":"6937_CR128","doi-asserted-by":"publisher","unstructured":"Gonzales MM, et al. Biological aging processes underlying cognitive decline and neurodegenerative disease. J Clin Invest. 2022;132(10). https:\/\/doi.org\/10.1172\/JCI158453.","DOI":"10.1172\/JCI158453"},{"key":"6937_CR129","doi-asserted-by":"publisher","unstructured":"Yang M, Matan-Lithwick S, Wang Y, De Jager PL, Bennett DA, Felsky D. Multi-omic integration via similarity network fusion to detect molecular subtypes of ageing. Brain Commun. 2023;5(2):fcad110. https:\/\/doi.org\/10.1093\/braincomms\/fcad110.","DOI":"10.1093\/braincomms\/fcad110"},{"issue":"2","key":"6937_CR130","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/hbm.24401","volume":"40","author":"JW Vogel","year":"2019","unstructured":"Vogel JW, et al. Data-driven approaches for tau-PET imaging biomarkers in Alzheimer\u2019s disease. Hum Brain Mapp. 2019;40(2):638\u201351. https:\/\/doi.org\/10.1002\/hbm.24401.","journal-title":"Hum. Brain Mapp."},{"issue":"1","key":"6937_CR131","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12883-020-01728-x","volume":"20","author":"L Teng","year":"2020","unstructured":"Teng L, et al. Predicting MCI progression with FDG-PET and cognitive scores: a longitudinal study. BMC Neurol. 2020;20(1):148. https:\/\/doi.org\/10.1186\/s12883-020-01728-x.","journal-title":"BMC Neurol."},{"issue":"1","key":"6937_CR132","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/ana.24546","volume":"79","author":"KA Johnson","year":"2016","unstructured":"Johnson KA, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79(1):110\u20139. https:\/\/doi.org\/10.1002\/ana.24546.","journal-title":"Ann. Neurol."},{"issue":"Pt 5","key":"6937_CR133","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/brain\/aww027","volume":"139","author":"R Ossenkoppele","year":"2016","unstructured":"Ossenkoppele R, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer\u2019s disease. Brain. 2016;139(Pt 5):1551\u201367. https:\/\/doi.org\/10.1093\/brain\/aww027.","journal-title":"Brain"},{"issue":"1","key":"6937_CR134","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.neulet.2008.04.021","volume":"438","author":"F Bai","year":"2008","unstructured":"Bai F, et al. Default-mode network activity distinguishes amnestic type mild cognitive impairment from healthy aging: a combined structural and resting-state functional MRI study. Neurosci Lett. 2008;438(1):111\u20135. https:\/\/doi.org\/10.1016\/j.neulet.2008.04.021.","journal-title":"Neurosci. Lett."},{"issue":"26","key":"6937_CR135","doi-asserted-by":"publisher","first-page":"8890","DOI":"10.1523\/JNEUROSCI.5698-11.2012","volume":"32","author":"MR Brier","year":"2012","unstructured":"Brier MR, et al. Loss of intranetwork and internetwork resting state functional connections with Alzheimer\u2019s disease progression. J Neurosci. 2012;32(26):8890\u20139. https:\/\/doi.org\/10.1523\/JNEUROSCI.5698-11.2012.","journal-title":"J. Neurosci."},{"key":"6937_CR136","doi-asserted-by":"publisher","unstructured":"Song Y, et al. Functional MRI-specific alterations in salience network in mild cognitive impairment: an ALE meta-analysis. Front Aging Neurosci. 2021;(13). https:\/\/doi.org\/10.3389\/fnagi.2021.695210.","DOI":"10.3389\/fnagi.2021.695210"},{"issue":"9","key":"6937_CR137","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1002\/hbm.25369","volume":"42","author":"B Ibrahim","year":"2021","unstructured":"Ibrahim B, et al. Diagnostic power of resting-state fMRI for detection of network connectivity in Alzheimer\u2019s disease and mild cognitive impairment: A systematic review. Hum Brain Mapp. 2021;42(9):2941\u201368. https:\/\/doi.org\/10.1002\/hbm.25369.","journal-title":"Hum. Brain Mapp."},{"issue":"4","key":"6937_CR138","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1093\/brain\/awz026","volume":"142","author":"N Franzmeier","year":"2019","unstructured":"Franzmeier N, et al. Functional connectivity associated with tau levels in ageing, Alzheimer\u2019s, and small vessel disease. Brain. 2019;142(4):1093\u2013107. https:\/\/doi.org\/10.1093\/brain\/awz026.","journal-title":"Brain"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06937-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06937-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06937-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:15:33Z","timestamp":1762521333000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06937-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":138,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6937"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06937-x","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"10 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was acquired from the institutional review boards of all participating institutions, and written informed consent was obtained from all ADNI participants at the time of enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1240"}}